Immuneering Announces Promising Phase 2a Trial Results

Immuneering ( (IMRX) ) has issued an announcement.

On June 17, 2025, Immuneering Corporation announced interim data from its Phase 2a clinical trial of atebimetinib, in combination with mGnP, for first-line pancreatic cancer patients. The trial showed promising results with an 81% disease control rate and a 39% overall response rate among 36 evaluable patients. Additionally, the 320 mg dose level demonstrated a 94% overall survival rate and 72% progression-free survival rate, with the treatment being generally well tolerated. The company plans to initiate a pivotal trial in 2026, pending regulatory feedback, and expects further data in the fourth quarter of 2025.

The most recent analyst rating on (IMRX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Immuneering stock, see the IMRX Stock Forecast page.

Spark’s Take on IMRX Stock

According to Spark, TipRanks’ AI Analyst, IMRX is a Underperform.

Immuneering’s stock is primarily challenged by its poor financial performance, with ongoing losses and negative cash flows posing significant risks. Technical indicators suggest bearish momentum, although the oversold RSI may hint at a potential rebound. Valuation metrics are unfavorable, highlighting persistent operational challenges and lack of profitability. The absence of significant earnings call or corporate events data limits further insights.

To see Spark’s full report on IMRX stock, click here.

More about Immuneering

Immuneering Corporation operates in the biotechnology industry, focusing on developing therapies for patients with advanced RAS- and/or RAF-mutant solid tumors. Their primary product is atebimetinib, a MEK inhibitor, which is being evaluated in clinical trials for its effectiveness in treating pancreatic cancer.

Average Trading Volume: 243,101

Technical Sentiment Signal: Hold

Current Market Cap: $85.29M

Find detailed analytics on IMRX stock on TipRanks’ Stock Analysis page.